These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30972018)

  • 1. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.
    Lingor P; Weber M; Camu W; Friede T; Hilgers R; Leha A; Neuwirth C; Günther R; Benatar M; Kuzma-Kozakiewicz M; Bidner H; Blankenstein C; Frontini R; Ludolph A; Koch JC;
    Front Neurol; 2019; 10():293. PubMed ID: 30972018
    [No Abstract]   [Full Text] [Related]  

  • 2. Compassionate Use of the ROCK Inhibitor Fasudil in Three Patients With Amyotrophic Lateral Sclerosis.
    Koch JC; Kuttler J; Maass F; Lengenfeld T; Zielke E; Bähr M; Lingor P
    Front Neurol; 2020; 11():173. PubMed ID: 32231638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).
    Wolff AW; Bidner H; Remane Y; Zimmer J; Aarsland D; Rascol O; Wyse RK; Hapfelmeier A; Lingor P
    Front Aging Neurosci; 2024; 16():1308577. PubMed ID: 38419648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants.
    Wolff AW; Peine J; Höfler J; Zurek G; Hemker C; Lingor P
    CNS Drugs; 2024 Apr; 38(4):291-302. PubMed ID: 38416402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol of RESCUE-ALS: A Phase 2,
    Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
    BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
    Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
    Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
    Vucic S; Menon P; Huynh W; Mahoney C; Ho KS; Hartford A; Rynders A; Evan J; Evan J; Ligozio S; Glanzman R; Hotchkin MT; Kiernan MC
    EClinicalMedicine; 2023 Jun; 60():102036. PubMed ID: 37396808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
    Takata M; Tanaka H; Kimura M; Nagahara Y; Tanaka K; Kawasaki K; Seto M; Tsuruma K; Shimazawa M; Hara H
    Br J Pharmacol; 2013 Sep; 170(2):341-51. PubMed ID: 23763343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
    Beghi E; Pupillo E; Bianchi E; Bonetto V; Luotti S; Pasetto L; Bendotti C; Tortarolo M; Sironi F; Camporeale L; Sherman AV; Paganoni S; Scognamiglio A; De Marchi F; Bongioanni P; Del Carratore R; Caponnetto C; Diamanti L; Martinelli D; Calvo A; Filosto M; Padovani A; Piccinelli SC; Ricci C; Dalla Giacoma S; De Angelis N; Inghilleri M; Spataro R; La Bella V; Logroscino G; Lunetta C; Tarlarini C; Mandrioli J; Martinelli I; Simonini C; Zucchi E; Monsurrò MR; Ricciardi D; Trojsi F; Riva N; Filippi M; Simone IL; Sorarù G; Spera C; Florio L; Messina S; Russo M; Siciliano G; Conte A; Saddi MV; Carboni N; Mazzini L;
    Eur J Neurol; 2023 Jan; 30(1):69-86. PubMed ID: 36148821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial.
    Oki R; Izumi Y; Nodera H; Sato Y; Nokihara H; Kanai K; Sonoo M; Urushitani M; Nishinaka K; Atsuta N; Kohara N; Shimizu T; Kikuchi H; Oda M; Ikeda K; Nagai M; Komai K; Kojima Y; Kuzume D; Isose S; Shimohama S; Abe K; Ito H; Noda K; Ishihara T; Morita M; Shimohata T; Teramukai S; Kagimura T; Noma K; Yanagawa H; Kuwabara S; Kaji R;
    JMIR Res Protoc; 2018 Dec; 7(12):e12046. PubMed ID: 30578206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.
    Al-Chalabi A; Shaw P; Leigh PN; van den Berg L; Hardiman O; Ludolph A; Aho VV; Sarapohja T; Kuoppamäki M
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1165-1170. PubMed ID: 31315908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
    Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
    Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
    Genge A; van den Berg LH; Frick G; Han S; Abikoff C; Simmons A; Lin Q; Patra K; Kupperman E; Berry JD
    JAMA Neurol; 2023 Oct; 80(10):1089-1097. PubMed ID: 37695623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
    Andrews JA; Meng L; Kulke SF; Rudnicki SA; Wolff AA; Bozik ME; Malik FI; Shefner JM
    JAMA Neurol; 2018 Jan; 75(1):58-64. PubMed ID: 29181534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.